Eli Lilly's Foundayo (Orforglipron) Launches at $25/Month for Insured Patients
Eli Lilly launched Foundayo on April 1 at $25/month for insured patients and $149 self-pay. The ATTAIN-1 trial showed 12.4% average body weight loss on the highest dose.
#Oral GLP-1
48 stories
Oral GLP-1 is the next pricing and access lever in the obesity market. Three threads define the field: Novo's oral semaglutide (Rybelsus and the higher-dose oral Wegovy), Lilly's small-molecule orforglipron (Foundayo, FDA-approved April 2026), and a longer tail of preclinical and Phase 1 candidates from Pfizer, Roche, Boehringer Ingelheim, and Chinese developers (Kailera-Hengrui's HRS-7535/KAI-7535 Phase 3 in China with 9.5-10.9% weight loss at Week 44; MindRank AI's MDR-001 in the Phase 3 MOBILE trial in China after a July 9, 2026 $52M Series B).
The two competing approaches matter. Peptide orals like oral semaglutide and oral Wegovy depend on salt-permeation-enhancer systems (SNAC) to survive the gut, which limits dose delivery and bioavailability. Small-molecule orals like orforglipron sidestep that limit but face their own selectivity and safety questions.
Indirect comparisons of oral Wegovy versus Foundayo have been mixed — HbA1c lead to Foundayo, weight loss possibly to oral Wegovy. Stories here cover head-to-heads, pipeline reads, and the long-term cost implications. See #orforglipron, #foundayo, and #oral-wegovy.
Amazon Pharmacy Adds FDA-Approved Oral Wegovy Pill
Amazon Pharmacy expanded access to the new oral Wegovy pill with both insurance and cash-pay options, signaling a broader retail push to capitalize on surging oral GLP-1 demand.
FDA Approves Eli Lilly Oral GLP-1 Foundayo — Rivalry With Oral Wegovy Begins
Eli Lilly's Foundayo (orforglipron) won FDA approval with aggressive pricing as low as $25/month with savings card. Medicare Part D coverage could bring costs to $50/month starting July 2026.
FDA Approves Orforglipron: First GLP-1 Pill Without Food or Water Restrictions
Orforglipron (Foundayo) is the first GLP-1 pill that can be taken at any time without food or water restrictions, a major differentiator from oral semaglutide which requires morning dosing on an empty stomach.
Indirect Analysis: Oral Semaglutide May Beat Orforglipron on Weight Loss
Published the day after Foundayo's FDA approval, a new indirect comparison found oral semaglutide may produce greater weight loss than orforglipron with fewer GI discontinuations.
Foundayo vs Oral Wegovy: Head-to-Head Comparison Analysis
Managed Healthcare Executive compares Foundayo (orforglipron) vs oral Wegovy (semaglutide). ACHIEVE-3 trial data showed Foundayo superior on HbA1c, but oral Wegovy may edge ahead on weight loss.
Foundayo Approval Intensifies Oral GLP-1 Market Competition Against Novo Nordisk
Foundayo's small-molecule design is easier to manufacture with fewer dosing restrictions than Novo Nordisk's peptide-based oral Wegovy. Analysts project Lilly's combined franchise could exceed $100 billion in peak revenue.
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
The FDA approved once-daily oral semaglutide (Wegovy) 25 mg as the first GLP-1 pill for weight loss, offering a convenient alternative to injections with comparable weight loss to the original injection.
FDA Approves Oral Wegovy Following Positive OASIS 4 Trial Results
FDA approved oral Wegovy (semaglutide) based on OASIS 4 trial showing significant improvements in glycemic control and cardiovascular risk factors. Novo Nordisk plans full US launch from North Carolina manufacturing.
5 Things to Know About the Oral GLP-1 Era
AJMC covers the oral GLP-1 era: participants on 25mg oral semaglutide saw ~16.6% weight loss when adherent, comparable to injectable outcomes. Discusses broader market implications.
Orforglipron and the Future of Oral GLP-1 Therapy
Pharmacy Times covers orforglipron's ability to cut A1C and drive meaningful weight loss with easier dosing than injections, potentially reshaping the GLP-1 treatment landscape.
AstraZeneca Builds Phase II Obesity Pipeline Including Oral GLP-1 and Peptide Agents
AstraZeneca has oral GLP-1 agents (AZD5004), peptide therapies (AZD6234), and dual agonist combinations in its Phase II obesity pipeline.